Second quarter summary

Important events, second quarter (April - June 2020):

• Abliva raises approximately MSEK 67 before deduction of issue costs in a preferential rights issue.
• Annual General Meeting in Abliva is held on 20 May 2020 in Lund, Sweden.
• NeuroVive Pharmaceutical AB changes its name to Abliva AB.
• Abliva arranges virtual Capital Markets Day on 23 June.
• Abliva completes the directed issue of MSEK 20 to Hadean Ventures.

Important events after the reporting period:

• Abliva has received positive feedback from the US Food and Drug Administration (“FDA”) on the KL1333 clinical development plan for the treatment of primary mitochondrial disease (PMD) at a pre-Investigational New Drug (“pre-IND”) meeting. Feedback was received on the existing KL1333 documentation to date and the remaining development plan, including the design of the clinical efficacy program in primary mitochondrial disease patients.

Financial information

April-June 2020*:

• Net revenues: KSEK 97 (85)
• Other operating income: KSEK 34 (1,000)
• Loss before tax: KSEK 20,312 (20,769)
• Loss per share: SEK 0.09 (0.14)
• Diluted loss per share: SEK 0.09 (0.14)

January-June 2020*:

• Net revenues: KSEK 105 (85)
• Other operating income: KSEK 34 (1,000)
• Loss before tax: KSEK 36,849 (34,591)
• Loss per share: SEK 0.18 (0.23)
• Diluted loss per share: SEK 0.18 (0.23)

* APM Alternative perfomance measures, see definition on page 19.